Neuronetics
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
| Company type | Public |
|---|---|
| Nasdaq: STIM Russell 2000 Index component | |
| Founded | 2003 |
| Headquarters | Malvern, PA, United States |
Key people | Keith J. Sullivan (President and CEO)[1][2] Stephen Furlong (CFO)[1]
Andrew Macan (Chief Commercial Officer)[3] |
Number of employees | 167 As of March 31, 2018[update][4] |
| Website | neurostar |
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for depression and other chronic psychiatric and neurological disorders based upon neuromodulation technology.
Neuronetics became "the first company to get FDA authorization for a transcranial magnetic stimulation (TMS) device to treat major depressive disorder in 2008."[5]
They manufacture a transcranial magnetic stimulation device.
References
- ^ a b c "Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer" (Press release). Neuronetics. Retrieved July 15, 2020.
- ^ "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
- ^ "NeuroStar Executive Team". Neuronetics.
- ^ a b "Neuronetics, Inc. (stim) IPO". NASDAQ.com.
- ^ "TMS pioneer Neuronetics gets breakthrough nod, CEO departs". MedTech Dive. Retrieved 2020-09-01.
External links
Categories:
- 2003 establishments in Pennsylvania
- American companies established in 2003
- Companies based in Chester County, Pennsylvania
- Health care companies based in Pennsylvania
- Health care companies established in 2003
- Manufacturing companies based in Pennsylvania
- Manufacturing companies established in 2003
- Medical technology companies of the United States
- Neurotechnology
- Physical psychiatric treatments
- Privately held companies based in Pennsylvania
- Treatment of depression